Search research articles
Contact Us
Filters
Showing results (181-190 of 499) with videos related to
Page
of 50
Sort By:
Current Treatment Options in Oncology
|
September 26, 2024
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer
Thierry André, Eric Van Cutsem, Julien Taieb, et al.
JAMA
|
May 6, 2010
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis
, Xavier Paoletti, Koji Oba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group
Jaffer A Ajani, Vladimir M Moiseyenko, Sergei Tjulandin, et al.
Clinical Colorectal Cancer
|
October 12, 2020
Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1
Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Current Opinion in Molecular Therapeutics
|
December 15, 2010
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials
Heinz Zwierzina, Alberto Bardelli, Fortunato Ciardiello, et al.
JCO Precision Oncology
|
October 11, 2024
Salvage Surgery for Unifocal Progressive Metastatic Mismatch Repair-Deficient GI Cancer Responding to Immune Checkpoint Inhibition
Pieterjan Perremans, Filip Van Herpe, Gertjan Rasschaert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2012
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies
Lisa Licitra, Stephan Störkel, Keith M Kerr, et al.
Clinical Epigenetics
|
February 16, 2020
DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer
Eva Galle, Bernard Thienpont, Sarah Cappuyns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group
Jaffer A Ajani, Vladimir M Moiseyenko, Sergei Tjulandin, et al.
Clinical Colorectal Cancer
|
October 20, 2019
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses
Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Page
of 50
Search research articles
Search
Showing results (181-190 of 499) with videos related to
Sort By:
Page
of 50
Current Treatment Options in Oncology
|
September 26, 2024
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer
Thierry André, Eric Van Cutsem, Julien Taieb, et al.
JAMA
|
May 6, 2010
Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis
, Xavier Paoletti, Koji Oba, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group
Jaffer A Ajani, Vladimir M Moiseyenko, Sergei Tjulandin, et al.
Clinical Colorectal Cancer
|
October 12, 2020
Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1
Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Current Opinion in Molecular Therapeutics
|
December 15, 2010
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials
Heinz Zwierzina, Alberto Bardelli, Fortunato Ciardiello, et al.
JCO Precision Oncology
|
October 11, 2024
Salvage Surgery for Unifocal Progressive Metastatic Mismatch Repair-Deficient GI Cancer Responding to Immune Checkpoint Inhibition
Pieterjan Perremans, Filip Van Herpe, Gertjan Rasschaert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 26, 2012
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies
Lisa Licitra, Stephan Störkel, Keith M Kerr, et al.
Clinical Epigenetics
|
February 16, 2020
DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer
Eva Galle, Bernard Thienpont, Sarah Cappuyns, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 2007
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group
Jaffer A Ajani, Vladimir M Moiseyenko, Sergei Tjulandin, et al.
Clinical Colorectal Cancer
|
October 20, 2019
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses
Heinz-Josef Lenz, Guillem Argiles, Takayuki Yoshino, et al.
Page
of 50